CClinicalTrials.gg
RecruitingNCT07440667Updated Mar 10, 2026

Restrictive vs Liberal Intraoperative Fluid Strategy and Postoperative Outcomes After Elective Cesarean Section

An interventional study of Restrictive intraoperative crystalloid fluid strategy (≤3 mL/kg/h) and Liberal intraoperative crystalloid fluid strategy (>3 mL/kg/h) in Cesarean Section, Postoperative Nausea and Vomiting (PONV) and Postdural Puncture Headache (PDPH), sponsored by Nigde Omer Halisdemir University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Nigde Omer Halisdemir University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Spinal anesthesia for elective cesarean section is frequently associated with hemodynamic instability and postoperative complications such as postoperative nausea and vomiting (PONV) and delayed gastrointestinal recovery. Although intraoperative fluid administration is routinely used to prevent spinal-induced hypotension, the optimal fluid strategy remains unclear. Both restrictive and liberal fluid approaches may influence maternal hemodynamics and postoperative outcomes through different physiological mechanisms.

This prospective, single-center, randomized controlled trial aims to compare restrictive (≤3 mL/kg/h) and liberal (>3 mL/kg/h) intraoperative crystalloid fluid strategies in patients undergoing elective cesarean section under spinal anesthesia. The primary outcome is the incidence of PONV within the first 24 hours postoperatively. Secondary outcomes include postdural puncture headache (PDPH), time to first flatus, hypotension frequency, and vasopressor requirements.

Read the detailed description

Spinal anesthesia is the preferred anesthetic technique for elective cesarean section; however, it is frequently associated with sympathetic blockade-induced hypotension. Intraoperative crystalloid administration is commonly used to mitigate hemodynamic instability, yet the optimal fluid strategy remains controversial. Liberal fluid administration may reduce the incidence or severity of hypotension but can contribute to tissue edema, including gastrointestinal wall edema, potentially delaying the recovery of bowel function. Conversely, restrictive fluid strategies may limit fluid overload but could increase vasopressor requirements and compromise splanchnic perfusion. The balance between these approaches and their influence on postoperative maternal outcomes has not been clearly established.

Postoperative nausea and vomiting (PONV) remains one of the most common and distressing complications following cesarean section. Hemodynamic fluctuations, vasopressor use, and visceral perfusion changes may all contribute to its development. In addition, delayed gastrointestinal recovery and postdural puncture headache (PDPH) are relevant postoperative outcomes that may be influenced by intraoperative fluid management.

This prospective, single-center, parallel-group randomized controlled trial is designed to compare two intraoperative crystalloid fluid strategies in patients undergoing elective cesarean section under spinal anesthesia. Patients will be randomized in a 1:1 ratio to receive either a restrictive (≤3 mL/kg/h) or a liberal (>3 mL/kg/h) intraoperative fluid approach. All other anesthetic procedures, spinal technique, and perioperative management will be standardized according to institutional protocol.

The primary outcome of the study is the incidence of PONV within the first 24 postoperative hours. Secondary outcomes include the incidence and severity of PDPH, time to first flatus as a marker of gastrointestinal recovery, frequency of hypotension, and vasopressor requirements. Intraoperative hemodynamic parameters and fluid administration data will be recorded prospectively.

The study aims to clarify whether intraoperative fluid volume influences postoperative maternal recovery and to contribute evidence toward optimizing perioperative fluid management in elective cesarean section.

02

Conditions studied

  • Cesarean Section
  • Postoperative Nausea and Vomiting (PONV)
  • Postdural Puncture Headache (PDPH)
  • Postoperative Ileus
  • Gastrointestinal Recovery

Keywords

  • Cesarean Section
  • Spinal Anesthesia
  • Intraoperative Fluid Therapy
  • Restrictive Fluid Strategy
  • Liberal Fluid Strategy
  • Postoperative Nausea and Vomiting
  • Postdural Puncture Headache
  • Gastrointestinal Recovery
  • Hypotension
  • Vasopressor Use
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female patients aged 18-45 years
  • ASA physical status II
  • Scheduled for elective cesarean section under spinal anesthesia
  • Provision of written informed consent

Exclusion criteria

Exclusion Criteria:

  • Emergency cesarean section
  • Preeclampsia or eclampsia
  • Known cardiac failure
  • Known renal failure
  • Known hepatic failure
  • Coagulopathy
  • Contraindication to spinal anesthesia
  • Conversion to general anesthesia
  • Major technical complications during spinal anesthesia
  • Refusal to participate
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Restrictive intraoperative fluid strategy (≤3 mL/kg/h)

    Participants undergoing elective cesarean section under spinal anesthesia will receive intraoperative crystalloid at a target average infusion rate of ≤3 mL/kg/h. Standardized spinal anesthesia technique and intraoperative management will be applied. Hypotension will be treated according to the predefined rescue protocol (e.g., ephedrine and/or additional fluid bolus as clinically indicated).

    Other: Restrictive intraoperative crystalloid fluid strategy (≤3 mL/kg/h)

  • Active comparator
    Liberal intraoperative fluid strategy (>3 mL/kg/h)

    Participants undergoing elective cesarean section under spinal anesthesia will receive intraoperative crystalloid at a target average infusion rate of \>3 mL/kg/h. Standardized spinal anesthesia technique and intraoperative management will be applied. Hypotension will be treated according to the predefined rescue protocol (e.g., ephedrine and/or additional fluid bolus as clinically indicated).

    Other: Liberal intraoperative crystalloid fluid strategy (>3 mL/kg/h)

Interventions

  • OtherRestrictive intraoperative crystalloid fluid strategy (≤3 mL/kg/h)

    Intraoperative crystalloid administration targeting an average rate of ≤3 mL/kg/h during elective cesarean section under spinal anesthesia.

  • OtherLiberal intraoperative crystalloid fluid strategy (>3 mL/kg/h)

    Intraoperative crystalloid administration targeting an average rate of \>3 mL/kg/h during elective cesarean section under spinal anesthesia.

05

What researchers measure

Primary outcomes

  1. Incidence of postoperative nausea and vomiting (PONV)

    Occurrence of nausea and/or vomiting within the first 24 hours after surgery, recorded as present or absent.

    Time frame: 0-24 hours postoperatively

Secondary outcomes

  1. Incidence and severity of postdural puncture headache (PDPH)

    Occurrence of postdural puncture headache (PDPH) within 72 hours postoperatively. Severity will be assessed using a standardized pain scale (e.g., numerical rating scale).

    Time frame: 24-72 hours postoperatively

  2. Time to first flatus

    Time (in hours) from the end of surgery to the first reported passage of flatus.

    Time frame: Up to 72 hours postoperatively

  3. Frequency of intraoperative hypotension

    Number of hypotensive episodes defined as systolic blood pressure \<90 mmHg or a decrease \>20% from baseline.

    Time frame: Intraoperative period

  4. Total intraoperative vasopressor dose

    Cumulative dose of ephedrine administered during surgery.

    Time frame: Intraoperative period

06

Study locations

1 of 1 sites recruiting
  • Niğde Ömer Halisdemir University Hospital
    Niğde, Merkez 51240, Turkey (Türkiye)
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be publicly shared due to institutional policies and ethical considerations related to patient confidentiality. De-identified data may be made available upon reasonable request to the corresponding investigator, subject to approval by the institutional ethics committee and data protection regulations.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07440667
Lead sponsor
Nigde Omer Halisdemir University
Responsible party
Seval KILBASANLI (MD, Nigde Omer Halisdemir University) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 4, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Mar 10, 2026

Study contacts

Pınar Erdoğan, Assoc. Prof.
Contact
pinar.erdogan@ohu.edu.tr
+905233646954
Seval Kılbasanlı, MD
Contact
pinar.erdogan@ohu.edu.tr
+905057246364
Pınar Erdoğan, Assoc Prof
principal investigator · Niğde Ömer Halisdemir University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion